Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 9/20 | 0.38 |
| ▸ | GCGR | P47871 | 4/20 | 0.38 |
| ▸ | CALML3 | P27482 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19933113 | 0.82 | GCGR (0.50) | AKR1C3AKR1C2PDE3BPDE3AMAPK14 | |
| SCHEMBL9303383 | 0.81 | PTGS1 (0.42) | AKR1C3AKR1C2PDE3BPDE3ALMNA | |
| SCHEMBL15022104 | 0.81 | MAPK13 (0.54) | PDE3BPDE3AMAPK14 | |
| SCHEMBL24296864 | 0.79 | ESR1 (0.33) | PDE3BPDE3AGRM5 | |
| SCHEMBL29534134 | 0.75 | AKR1C3 (0.50) | AKR1C3AKR1C2PDE3BPDE3AGRM5 | |
| SCHEMBL20654512 | 0.75 | AKR1C3 (0.50) | AKR1C3AKR1C2PDE3BPDE3AGRM5 | |
| SCHEMBL11303324 | 0.74 | TTR (0.42) | PDE3BPDE3ALMNA | |
| SCHEMBL21652626 | 0.74 | LMNA (0.50) | AKR1C3AKR1C2PDE3BPDE3AMAPK14 | |
| SCHEMBL31116972 | 0.72 | ALDH1A1 (0.34) | AKR1C3AKR1C2PDE3BPDE3AGRM5 | |
| SCHEMBL140223 | 0.72 | HDAC8 (0.71) | HDAC8MAPK14LMNAMAPTAAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575150-B2 | Triazole derivatives for treatment of Alzheimer's disease | MERCK SHARP & DOHME CORP. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20120022044-A1 | TRIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LLC | 2012-01-26 | — | — | US | disclosed |
| EP-2378879-A1 | TRIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | Merck Sharp & Dohme Corp. (US) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010071741-A1 | TRIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME CORP. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022044-A1 | TRIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | MAPT, BACE1, APP | HDAC8 367/4885AKR1C3 473/4885AKR1C2 469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.